X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share from the same period last year. The company reported quarterly sales of $8.806 million which beat the analyst consensus estimate of $2.420 million by 263.88 percent. This is a 346.33 percent increase over sales of $1.973 million the same period last year.